FR20C1032I2 - Inhibiteurs de beta-lactamase - Google Patents

Inhibiteurs de beta-lactamase

Info

Publication number
FR20C1032I2
FR20C1032I2 FR20C1032C FR20C1032C FR20C1032I2 FR 20C1032 I2 FR20C1032 I2 FR 20C1032I2 FR 20C1032 C FR20C1032 C FR 20C1032C FR 20C1032 C FR20C1032 C FR 20C1032C FR 20C1032 I2 FR20C1032 I2 FR 20C1032I2
Authority
FR
France
Prior art keywords
beta
lactamase inhibitors
lactamase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1032C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of FR20C1032I1 publication Critical patent/FR20C1032I1/fr
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of FR20C1032I2 publication Critical patent/FR20C1032I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
FR20C1032C 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase Active FR20C1032I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1153308P 2008-01-18 2008-01-18
EP09701487.2A EP2231667B1 (en) 2008-01-18 2009-01-15 Beta-lactamase inhibitors

Publications (2)

Publication Number Publication Date
FR20C1032I1 FR20C1032I1 (pt) 2020-02-10
FR20C1032I2 true FR20C1032I2 (fr) 2022-07-29

Family

ID=40642204

Family Applications (3)

Application Number Title Priority Date Filing Date
FR20C1032C Active FR20C1032I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase
FR20C1031C Active FR20C1031I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase
FR20C1030C Active FR20C1030I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase

Family Applications After (2)

Application Number Title Priority Date Filing Date
FR20C1031C Active FR20C1031I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase
FR20C1030C Active FR20C1030I2 (fr) 2008-01-18 2020-07-10 Inhibiteurs de beta-lactamase

Country Status (38)

Country Link
US (2) US8487093B2 (pt)
EP (2) EP2231667B1 (pt)
JP (3) JP5038509B2 (pt)
KR (2) KR101800610B1 (pt)
CN (2) CN101918407B (pt)
AU (1) AU2009206119C1 (pt)
BR (1) BRPI0906871B1 (pt)
CA (1) CA2712783C (pt)
CO (1) CO6331438A2 (pt)
CR (1) CR11626A (pt)
CY (5) CY1114900T1 (pt)
DK (2) DK2231667T3 (pt)
DO (1) DOP2010000218A (pt)
EC (2) ECSP10010345A (pt)
ES (2) ES2533826T3 (pt)
FR (3) FR20C1032I2 (pt)
HN (1) HN2010001395A (pt)
HR (2) HRP20131123T1 (pt)
HU (2) HUS000504I2 (pt)
IL (1) IL206395A (pt)
LT (3) LTPA2020517I1 (pt)
LU (1) LUC00165I2 (pt)
MA (1) MA32025B1 (pt)
ME (1) ME02089B (pt)
MX (1) MX2010007823A (pt)
MY (1) MY162532A (pt)
NI (1) NI201000115A (pt)
NL (3) NL301051I2 (pt)
NO (3) NO2020022I1 (pt)
NZ (1) NZ586861A (pt)
PL (2) PL2231667T3 (pt)
PT (2) PT2666774E (pt)
RS (2) RS53862B1 (pt)
RU (1) RU2445314C9 (pt)
SI (2) SI2666774T1 (pt)
UA (1) UA101966C2 (pt)
WO (1) WO2009091856A2 (pt)
ZA (1) ZA201005333B (pt)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
KR102143660B1 (ko) * 2011-06-17 2020-08-11 화이자 안티-인펙티브스 에이비 트랜스-7-옥소-6-(술포옥시)-1,6-디아자비시클로[3,2,1]옥탄-2-카르복스아미드 및 그의 염을 포함하는 헤테로시클릭 화합물의 제조 방법
RU2578370C2 (ru) * 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
MX340533B (es) * 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CN104159587A (zh) * 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
KR20150003777A (ko) 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
SG11201407295YA (en) 2012-05-08 2014-12-30 Codexis Inc Biocatalysts and methods for hydroxylation of chemical compounds
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
JPWO2014069351A1 (ja) * 2012-11-01 2016-09-08 株式会社カネカ 光学活性二環式ウレア化合物の製造方法
CN105026407B (zh) 2012-12-07 2017-09-08 维纳拓尔斯制药公司 β‑内酰胺酶抑制剂
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
KR20150103270A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
KR101774132B1 (ko) 2013-03-08 2017-09-01 욱크하르트 리미티드 (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법
BR112015021186A2 (pt) 2013-03-08 2017-07-18 Wockhardt Ltd processo para a preparação de (2s,5r)-7-oxo-6-sulfóxi-2-[((3r)-pirrolidina-3-carbonil)-hidrazino carbonil]-1,6-diaza-biciclo[3.2.1]octano
AU2013399862B2 (en) * 2013-03-08 2016-07-14 Wockhardt Limited A process for preparation of (2S, 5R)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
CN108191864A (zh) 2013-03-08 2018-06-22 沃克哈特有限公司 制备氧代磺酰氧基[(哌啶羰基)-肼基羰基]二氮杂-双环辛烷的方法
CA2904089C (en) * 2013-03-08 2017-05-02 Wockhardt Limited A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
AU2014278556B2 (en) 2013-06-10 2018-07-19 Merck Sharp & Dohme Llc Preparation of tert-butyl 4-((1R,2S,5R)-6- (benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2- carboxamido)piperidine-1-carboxylate
DK3050883T3 (da) 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
EP3613740A1 (en) * 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
WO2015079329A2 (en) * 2013-11-26 2015-06-04 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
MX373444B (es) 2014-03-24 2020-04-30 Novartis Ag Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas.
IN2014MU01196A (pt) * 2014-03-29 2015-10-02 Wockhardt Ltd
IN2014MU01195A (pt) * 2014-03-29 2015-10-02 Wockhardt Ltd
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
SI3140310T1 (sl) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli in njihova uporaba
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
PT3154989T (pt) 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
KR102542392B1 (ko) * 2014-11-17 2023-06-09 엔타시스 테라퓨틱스 리미티드 내성 박테리아 감염의 치료를 위한 배합물 치료제
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2812848T3 (es) 2014-12-02 2021-03-18 Merck Sharp & Dohme Proceso para la preparación de 4-((2S,5R)-6-(benciloxi)-7-oxo-1,6-diazabiciclo[3.2.1]octano-2-carboxamido)piperidin-1-carboxilato de terc-butilo y análogos del mismo
RU2732129C2 (ru) 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TW201639853A (zh) * 2015-03-31 2016-11-16 木塔比利斯公司 雜環化合物及其於預防或治療細菌感染之用途
CA2983674A1 (en) * 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
EP3281942A4 (en) * 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
CA3000087A1 (en) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10501464B2 (en) * 2015-12-11 2019-12-10 Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
WO2017136254A1 (en) 2016-02-04 2017-08-10 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
WO2017167218A1 (zh) * 2016-03-31 2017-10-05 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
WO2017213758A1 (en) 2016-06-09 2017-12-14 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
CN114591223B (zh) * 2016-09-16 2025-01-24 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物
US10464937B2 (en) * 2016-09-19 2019-11-05 Merck Sharp & Dohme Corp. Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途
MA47743A (fr) 2017-03-06 2020-01-15 Venatorx Pharmaceuticals Inc Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
CN108619141B (zh) * 2017-03-16 2021-09-10 山东轩竹医药科技有限公司 一种抗菌组合物及其用途
NZ758200A (en) 2017-05-08 2025-12-19 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
ES2946917T3 (es) 2017-07-21 2023-07-27 Antabio Sas Compuestos químicos
CN109568323B (zh) * 2017-09-29 2022-09-30 吉林四环制药有限公司 抗菌组合物及其用途
MX2020003495A (es) 2017-10-11 2020-09-18 Qpex Biopharma Inc Derivados de acido boronico y sintesis de los mismos.
JP6974614B2 (ja) 2017-12-01 2021-12-01 チールー ファーマシューティカル カンパニー、リミテッド β−ラクタマーゼ阻害剤の結晶形およびその製造方法
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
KR102769880B1 (ko) * 2018-01-25 2025-02-20 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. β-락타마제 억제제 및 그 용도
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
SG11202101255UA (en) * 2018-08-09 2021-03-30 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3670512A1 (en) * 2018-12-18 2020-06-24 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN119707784A (zh) 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
ES2991492T3 (es) * 2018-10-01 2024-12-03 Arixa Pharmaceuticals Inc Derivados de relebactam y usos de los mismos
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
CN113382713A (zh) 2018-11-29 2021-09-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物及其用途
AU2020237440B2 (en) 2019-03-12 2022-10-20 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
CN114206851B (zh) 2019-04-26 2025-02-11 默沙东有限责任公司 可用于制备(2s,5r)-7-氧代-n-哌啶-4-基-6-(硫酸基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的中间体的制备方法
JP7647110B2 (ja) * 2020-01-22 2025-03-18 日油株式会社 ポリエーテルエステル化合物
BR112022022367A2 (pt) 2020-05-05 2023-01-10 Qpex Biopharma Inc Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos
EP4146650B1 (en) 2020-09-01 2026-01-21 Ningxia Academy of Agriculture and Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
US20250302846A1 (en) * 2022-05-11 2025-10-02 The Regents Of The University Of Colorado A Body Corporate Antibiotic composition and methods of use thereof
CN117384169B (zh) * 2022-07-05 2025-10-17 福安药业集团重庆三禾兴医药科技有限公司 一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071843A (en) 1978-07-24 1991-12-10 Merck & Co., Inc. Combination of 2-substituted carbapenems with dipeptidase inhibitors
US4616038A (en) 1978-07-24 1986-10-07 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4880793A (en) 1978-07-24 1989-11-14 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
US4539208A (en) 1980-09-17 1985-09-03 Merck & Co., Inc. Combination of thienamycin-type antibiotics with dipeptidase inhibitors
DK0508234T3 (da) 1991-04-11 1996-10-28 Hoffmann La Roche Beta-lactamer
HUT74682A (en) 1993-12-29 1997-01-28 Pfizer Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them
JP3199300B2 (ja) * 1994-05-09 2001-08-13 三共株式会社 １−メチルカルバペネム誘導体
JP2965922B2 (ja) * 1995-12-21 1999-10-18 三共株式会社 １−メチルカルバペネム誘導体
EP0882728B1 (en) 1995-12-21 2002-09-04 Sankyo Company Limited 1-methylcarbapenem derivatives
JP2955276B2 (ja) * 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤
JP4490517B2 (ja) * 1998-03-19 2010-06-30 富山化学工業株式会社 ５−デオキシ−５−アルカノイルアミノ−β−Ｄ−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤
MXPA02000246A (es) 1999-07-06 2003-08-20 Methylgene Inc Inhibidores de °-lactamasa de sulfonamidometil fosfonato.
MXPA02001394A (es) 1999-08-10 2002-08-12 British Biotech Pharm Agentes antibacterianos.
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2002212182A (ja) * 2000-11-16 2002-07-31 Sankyo Co Ltd １−メチルカルバペネム誘導体
HUP0303204A3 (en) 2000-11-16 2010-04-28 Sankyo Co 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2004043438A (ja) * 2002-05-15 2004-02-12 Sankyo Co Ltd １−メチルカルバペネム誘導体を含有する医薬
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
CA2531728A1 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
WO2005033129A1 (de) 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibakterielle amid-makrozyklen
EP1751527A2 (en) 2004-02-24 2007-02-14 SSCI, Inc. Analysis and screening of solid forms using the atomic pair distribution function
CA2783572C (en) * 2005-12-07 2016-08-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa

Also Published As

Publication number Publication date
FR20C1030I2 (fr) 2021-08-27
AU2009206119B2 (en) 2012-06-07
KR101800610B1 (ko) 2017-11-23
DOP2010000218A (es) 2010-08-31
CY2020023I1 (el) 2020-11-25
MY162532A (en) 2017-06-15
EP2666774B1 (en) 2015-01-07
CY2020024I1 (el) 2020-11-25
MX2010007823A (es) 2010-08-10
RS53052B (sr) 2014-04-30
WO2009091856A2 (en) 2009-07-23
KR20160099117A (ko) 2016-08-19
UA101966C2 (xx) 2013-05-27
RU2445314C9 (ru) 2013-04-10
NZ586861A (en) 2011-12-22
FR20C1031I2 (fr) 2022-07-29
EP2666774A1 (en) 2013-11-27
NO2020022I1 (no) 2020-08-10
BRPI0906871B1 (pt) 2021-09-28
HK1186180A1 (en) 2014-03-07
IL206395A (en) 2015-04-30
HN2010001395A (es) 2012-11-12
NO2020023I1 (no) 2020-08-10
DK2231667T3 (da) 2013-12-16
KR101648728B1 (ko) 2016-08-17
HK1143809A1 (en) 2011-01-14
FR20C1031I1 (pt) 2020-02-10
SI2666774T1 (sl) 2015-04-30
EP2231667A2 (en) 2010-09-29
DK2666774T3 (en) 2015-03-23
ECSP10010345A (es) 2010-08-31
HUS000513I2 (hu) 2021-03-29
CY2020024I2 (el) 2020-11-25
FR20C1032I1 (pt) 2020-02-10
RU2445314C1 (ru) 2012-03-20
CN102827067A (zh) 2012-12-19
LTPA2020517I1 (lt) 2020-07-27
US8487093B2 (en) 2013-07-16
ECSP10010568A (es) 2010-11-30
WO2009091856A3 (en) 2009-12-03
ME02089B (me) 2014-04-30
CY2020025I1 (el) 2020-11-25
PL2231667T3 (pl) 2014-01-31
LTPA2020516I1 (lt) 2020-07-27
SI2231667T1 (sl) 2013-12-31
NL301050I2 (nl) 2020-09-03
JP5422020B2 (ja) 2014-02-19
HUS2000024I1 (hu) 2021-03-29
JP2011510012A (ja) 2011-03-31
CN101918407B (zh) 2014-02-26
ES2533826T3 (es) 2015-04-15
HRP20150269T1 (hr) 2015-04-24
CN102827067B (zh) 2015-09-23
HRP20131123T1 (hr) 2013-12-20
US20110294777A1 (en) 2011-12-01
LTC2666774I2 (lt) 2022-01-25
IL206395A0 (en) 2010-12-30
LTC2231667I2 (lt) 2021-07-26
CA2712783A1 (en) 2009-07-23
HUS2000023I1 (hu) 2021-03-29
LUC00165I2 (pt) 2021-08-16
NI201000115A (es) 2011-07-08
NO2020024I1 (no) 2020-08-10
NL301052I2 (nl) 2026-02-03
PT2666774E (pt) 2015-04-13
JP2012214475A (ja) 2012-11-08
CN101918407A (zh) 2010-12-15
CY1114900T1 (el) 2016-12-14
MA32025B1 (fr) 2011-01-03
PT2231667E (pt) 2013-12-13
ES2433744T3 (es) 2013-12-12
FR20C1030I1 (fr) 2020-02-10
KR20100130176A (ko) 2010-12-10
CA2712783C (en) 2013-03-19
LTPA2020518I1 (lt) 2020-07-27
CY2020025I2 (el) 2020-11-25
AU2009206119A1 (en) 2009-07-23
JP2011207900A (ja) 2011-10-20
ZA201005333B (en) 2011-04-28
CY2020023I2 (el) 2020-11-25
JP5038509B2 (ja) 2012-10-03
JP5597164B2 (ja) 2014-10-01
PL2666774T3 (pl) 2015-06-30
RS53862B1 (sr) 2015-08-31
CY1116243T1 (el) 2017-03-15
BRPI0906871A2 (pt) 2020-07-28
CR11626A (es) 2010-09-13
CO6331438A2 (es) 2011-10-20
NL301051I2 (nl) 2020-09-03
AU2009206119C1 (en) 2016-05-26
HUS000504I2 (hu) 2021-03-29
US20130274475A1 (en) 2013-10-17
EP2231667B1 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
FR20C1031I2 (fr) Inhibiteurs de beta-lactamase
CY2017016I2 (el) Αναστολεις πρωτεασωματος
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0917808A2 (pt) inibidores de cmet
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
BRPI0918564A2 (pt) inibidores
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0814797A2 (pt) Inibidores dna-pk
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0806898A2 (pt) Inibidores de mek
EP2374802A4 (en) INHIBITOR OF KYNURENINE PRODUCTION
EP2467382A4 (en) AMINO-TETRA HYDRO-pyridopyrimidine PDE10 INHIBITORS
DK2066662T3 (da) Serinhydrolaseinhibitorer
EP2435048A4 (en) RADIOACTIVELY MARKED PDE10 HEMMER
DK2240506T3 (da) IAP inhibitorer
AT507449A3 (de) Dämmstoffbefestiger
BRPI0918966A2 (pt) inibidores de protease
BRPI0912564A2 (pt) inibidores de jnk
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0919073A2 (pt) inibidores de protease
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
FI20080062A0 (fi) Työkalu